Speckle-Tracking Echocardiography in Assessment of Breast Cancer Therapy-Related Subclinical Cardiac Dysfunction
Authors:
- B. A. AkbalaevaBAB. A. Akbalaeva
- L. V. ShulzhenkoLSL. V. Shulzhenko
- I. V. PershukovIPI. V. Pershukov
- N. Raiimbek UuluNUN. Raiimbek Uulu
- T. A. BatyralievTBT. A. Batyraliev
- O. V. GurovichOGO. V. Gurovich
- V. V. VinogradskaiaVVV. V. Vinogradskaia
- N. T. JainakbayevNJN. T. Jainakbayev
- A. O. SeidalinASA. O. Seidalin
- M. R. KamaliyevaMKM. R. Kamaliyeva
Open Access
- 28 April 2024
- journal article
- research article
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 2,p. 8-15
Abstract
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a new term that encompasses a wide range of potential manifestations and is etiologically associated with a wide variety of cancer treatments. Detection of early subclinical cardiac dysfunction is of great clinical importance.Objective: To assess subclinical CTRCD in women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab. We prospectively enrolled women aged 18-75 years with an established diagnosis of HER2-positive locally advanced or metastatic breast cancer across 3 centers.Material and methods: We monitored 122 women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab using speckle-tracking echocardiography. Based on the treatment protocol, we formed 3 comparison blocks: block 1 (chemotherapy: doxorubicin+cyclophosphamide); block 2 (chemotherapy+targeted therapy: docetaxel+trastuzumab), and block 3 (targeted therapy: trastuzumab).Results: The rate of subclinical CTRCD detection was high and exceeded 20%-30% in all comparison blocks after the 3rd course of chemotherapy, chemotherapy+targeted therapy, and targeted therapy. The rate of subclinical CTRCD increased significantly from the 1st to the 2nd, from the 2nd to the 3rd, from the 3rd to the 4th therapy courses in each block. Comparisons between the blocks were significant only after the 4th course of chemotherapy and the 4th course of targeted therapy (Yates-corrected chi-square, P=.0394); all the other comparisons between the blocks were not significant in terms of subclinical CTRCD rate.Discussion: Given the growing number of patients with breast cancer, such frequent monitoring of the cardiac function is likely to improve the quality of cancer treatment and might have a positive impact on the overall survival of patients with breast cancer. Conclusions: Criteria for frequency of echocardiographic monitoring of cardiac dysfunction in patients with malignant tumors, especially with HER2-positive breast cancer, should be revised.Keywords
This publication has 22 references indexed in Scilit:
- Erratum to: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)European Heart Journal, 2023
- Global Longitudinal Strain Monitoring to Guide Cardioprotective Medications During Anthracycline TreatmentCurrent Oncology Reports, 2022
- Early Detection of Anthracycline- and Trastuzumab-Induced Cardiotoxicity: Value and Optimal Timing of Serum Biomarkers and Echocardiographic ParametersESC Heart Failure, 2022
- Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementEuropean Heart Journal, 2021
- Cancer treatment-related cardiovascular disease: Current status and future research prioritiesBiochemical Pharmacology, 2021
- Cardio-Oncology Services: rationale, organization, and implementationEuropean Heart Journal, 2018
- Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicityEuropean Heart Journal - Cardiovascular Imaging, 2017
- Intervendor Variability of Two-Dimensional Strain Using Vendor-Specific and Vendor-Independent SoftwareJournal of the American Society of Echocardiography, 2015
- Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-OncologyMayo Clinic Proceedings, 2014
- Current and Evolving Echocardiographic Techniques for the Quantitative Evaluation of Cardiac Mechanics: ASE/EAE Consensus Statement on Methodology and IndicationsJournal of the American Society of Echocardiography, 2011